Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass
A Prospective Randomized Pilot Study to Evaluate the Effect of Preoperative Antithrombin Supplementation on Postoperative Levels of Antithrombin in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Lombardy
-
Milano, Lombardy, Italy, 20097
- IRCCS Policlinico San Donato
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female
- At least 18 years of age
- Subject needed elective cardiac surgery with cardiopulmonary bypass except for heart transplantation
- Subject had a baseline ATIII level of less than 100% and equal to or above 60%
- Subject signed the informed consent form
- Subject was willing to comply with all aspects of the protocol, including blood sampling, for the total duration of the study
Exclusion Criteria:
- Documented congenital ATIII deficiency or ATIII levels below 60%
- Subject had a baseline ATIII level of 100% or higher
- Subject needed emergency (non-elective) surgery
- Subject needed heart transplantation
- History of anaphylactic reaction(s) to blood or blood components
- Allergies to excipients
- Subject was pregnant
- Subject had any medical condition that according to the investigators judgment worsens the surgical outcome above the expected
- Subject had any medical condition which is likely to interfere with the evaluation of the study treatment and/or the satisfactory conduct of the trial according to the investigators judgment
- Subject had participated in any another investigational study within the last 30 days previous to the inclusion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Antithrombin III treatment group
Preoperative ATIII supplementation administered immediately after anesthesia induction
|
Single dose of antithrombin III sufficient to achieve a preoperative level of 120%
Other Names:
|
|
No Intervention: Control group
No preoperative ATIII supplementation administered
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative ATIII Levels at the ICU Admission
Time Frame: ICU admission
|
Measurement of postoperative ATIII functional activity at ICU admission
|
ICU admission
|
|
Percentage of Subjects With ATIII Levels of 58% or Higher at ICU Admission
Time Frame: ICU admission
|
Percentage of subjects with ATIII levels of 58% functional activity or higher at ICU admission
|
ICU admission
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Subjects With Postoperative Myocardial Infarction
Time Frame: During ICU stay (maximum 70 days)
|
Percentage of subjects with postoperative myocardial infarction defined through enzymatic criteria plus new Q-waves at the electrocardiogram
|
During ICU stay (maximum 70 days)
|
|
Percentage of Subjects With Adverse Neurologic Outcome
Time Frame: During ICU stay (maximum 70 days)
|
Percentage of subjects with adverse neurologic outcome defined as: coma, stroke or psychotic behaviors lasting >12 hours after extubation
|
During ICU stay (maximum 70 days)
|
|
Percentage of Patients With Thromboembolic Events
Time Frame: During ICU stay (maximum 70 days)
|
Percentage of subjects with thromboembolic events defined as perioperative myocardial infarction, stroke, mesenteric infarction, peripheral thromboembolism and pulmonary embolism
|
During ICU stay (maximum 70 days)
|
|
ICU Stay Duration
Time Frame: During ICU stay (maximum 70 days)
|
During ICU stay (maximum 70 days)
|
|
|
In-hospital Postoperative Mortality
Time Frame: 70 days after ICU admission (maximum)
|
70 days after ICU admission (maximum)
|
|
|
Heparin Resistance
Time Frame: Immediately after anesthesia induction
|
Percentage of subjects with heparin resistance defined as failure to reach an activated clotting time >450 seconds after a dose of up to 400 IU/kg of heparin, or failure to maintain this activated clotting time value despite heparin supplementations of 100 IU/kg per each dose with an interval of at least 30 minutes between doses
|
Immediately after anesthesia induction
|
|
Postoperative Blood Loss in First 12 Hours
Time Frame: ICU admission through 12 hours post-operative
|
Blood loss defined as the amount of blood collected in the cardiotomy reservoir from ICU admission through the following 12 hours
|
ICU admission through 12 hours post-operative
|
|
Need for Blood Products
Time Frame: During ICU stay (maximum 70 days)
|
Number of units of packed red blood cells, fresh frozen plasma, and/or platelets needed
|
During ICU stay (maximum 70 days)
|
|
Percentage of Subjects Needing Surgical Re-exploration
Time Frame: During ICU stay (maximum 70 days)
|
Percentage of subjects needing surgical re-exploration resulting from bleeding
|
During ICU stay (maximum 70 days)
|
|
Percentage of Subjects With Low Cardiac Syndrome
Time Frame: During ICU stay (maximum 70 days)
|
Percentage of subjects with low cardiac syndrome defined as the need for major inotropic support or intra-aortic balloon pump
|
During ICU stay (maximum 70 days)
|
|
Percentage of Subjects With Renal Dysfunction
Time Frame: During ICU stay (maximum 70 days)
|
Percentage of subjects with renal dysfunction defined as an increase of serum creatinine levels to >2.0 and twice the baseline level or need for renal replacement therapy
|
During ICU stay (maximum 70 days)
|
|
Mechanical Ventilation Duration
Time Frame: During ICU stay (maximum 70 days)
|
During ICU stay (maximum 70 days)
|
|
|
Length of Hospital Stay
Time Frame: During ICU stay (maximum 70 days)
|
Length of hospital stay (days) in both groups was defined as the discharge date minus the surgery date plus 1 day, during a maximum of 70 days after ICU admission.
|
During ICU stay (maximum 70 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Marco Ranucci, MD, IRCCS Policlinico San Donato, Milano
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Hematologic Diseases
- Blood Coagulation Disorders, Inherited
- Genetic Diseases, Inborn
- Blood Protein Disorders
- Blood Coagulation Disorders
- Thrombophilia
- Antithrombin III Deficiency
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Serine Proteinase Inhibitors
- Anticoagulants
- Antithrombins
- Antithrombin III
Other Study ID Numbers
Other Study ID Numbers
- IG0801
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.